To gain further insight into these differences, we performed gene set enrichment analysis (GSEA) on tumourspheres subjected to dual-MET-FGFR inhibition and found negative enrichment indicating loss of gene signatures associated with EMT, stemness, breast cancer progenitors, and Met signalling when compared to DMSO-treated control tumourspheres (Fig. 4b, d). The gene discussed is MET; the disease is breast carcinoma.